On the 15th of November, I came across an online update that the FDA had approved crizanlizumab-tmca as the first ever available targeted therapy for sickle cell disease.
The FDA announced that Novartis had been given the green light to market this drug aka Adakveo (which is the brand name).
Related Post: 5 DRUGS FOR SICKLE CELL TREATMENT TO ASK YOUR DOCTOR ABOUT
It was reported that this would be a monthly infusion drug that is said to cut the occurence of sickle cell pain episodes in half. This drug carries a price list of roughly $85,000 to $113,000 per year depending on dosing. In other words, the wholesale acquisition cost will be at least $2,357 per vial, meaning that the expected usage of 3 or 4 vials a month would end up costing about $7,071 or $9,428 per month according to publication, Fierce Pharma.
A Novartis advisory board member says the drug appears to work better the longer patients receive it. Adakveo specifically inhibits Selectin, a substance that contributes to cells sticking together that leads to vaso-occlusive crisis. The approval of this drug was based on the results of a clinical trial of almost 200 patients with sickle cell disease. Patients treated with Adakveo experienced fewer hospital visits from crisis during the study. It also delayed the time that patients first experienced vaso-occlusive crisis after starting treatment.
Noted side effects were nausea, back pain, joint pain and fever, hence patients prescribed this infusion therapy drug need to be monitored for reactions and to be discontinued if those reactions become serious.
Ask your doctor about Crizanlizumab-tmca on your next visit to learn more and see if you can start using it too.
Being that Thanksgiving this year is on Thursday, there will not be any posts going up to allow all of us enjoy this time with our families. Also, I will not be posting on Saturday either because I want to use this day to get most if not all of my Christmas shopping done so the next post going up will be another Sickle Cell one.
Always Love 💕